Literature DB >> 20043990

Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization.

Ji Chu1, Hui Zheng, Yuhan Zhang, Horace H Loh, Ping-Yee Law.   

Abstract

Desensitization of the micro-opioid receptor (MOR) has been implicated as an important regulatory process in the development of tolerance to opiates. Monitoring the release of intracellular Ca(2+) ([Ca(2+)](i)), we reported that [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO)-induced receptor desensitization requires receptor phosphorylation and recruitment of beta-arrestins (betaArrs), while morphine-induced receptor desensitization does not. In current studies, we established that morphine-induced MOR desensitization is protein kinase C (PKC)-dependent. By using RNA interference techniques and subtype specific inhibitors, PKCepsilon was shown to be the PKC subtype activated by morphine and the subtype responsible for morphine-induced desensitization. In contrast, DAMGO did not increase PKCepsilon activity and DAMGO-induced MOR desensitization was not affected by modulating PKCepsilon activity. Among the various proteins within the receptor signaling complex, Galphai2 was phosphorylated by morphine-activated PKCepsilon. Moreover, mutating three putative PKC phosphorylation sites, Ser(44), Ser(144) and Ser(302) on Galphai2 to Ala attenuated morphine-induced, but not DAMGO-induced desensitization. In addition, pretreatment with morphine desensitized cannabinoid receptor CB1 agonist WIN 55212-2-induced [Ca(2+)](i) release, and this desensitization could be reversed by pretreating the cells with PKCepsilon inhibitor or overexpressing Galphai2 with the putative PKC phosphorylation sites mutated. Thus, depending on the agonist, activation of MOR could lead to heterologous desensitization and probable crosstalk between MOR and other Galphai-coupled receptors, such as the CB1. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043990      PMCID: PMC2833358          DOI: 10.1016/j.cellsig.2009.12.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  69 in total

1.  mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis.

Authors:  Carl Rios; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

2.  Phosphorylation of Galpha11 protein contributes to agonist-induced desensitization of 5-HT2A receptor signaling.

Authors:  Ju Shi; Bozena Zemaitaitis; Nancy A Muma
Journal:  Mol Pharmacol       Date:  2006-10-20       Impact factor: 4.436

3.  The linoleic acid derivative DCP-LA selectively activates PKC-epsilon, possibly binding to the phosphatidylserine binding site.

Authors:  Takeshi Kanno; Hideyuki Yamamoto; Takahiro Yaguchi; Rika Hi; Takeshi Mukasa; Hirokazu Fujikawa; Tetsu Nagata; Satoshi Yamamoto; Akito Tanaka; Tomoyuki Nishizaki
Journal:  J Lipid Res       Date:  2006-03-06       Impact factor: 5.922

Review 4.  Beta-arrestin-biased ligands at seven-transmembrane receptors.

Authors:  Jonathan D Violin; Robert J Lefkowitz
Journal:  Trends Pharmacol Sci       Date:  2007-07-20       Impact factor: 14.819

5.  Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells.

Authors:  Elizabeth A Johnson; Sue Oldfield; Ellen Braksator; Ana Gonzalez-Cuello; Daniel Couch; Kellie J Hall; Stuart J Mundell; Chris P Bailey; Eamonn Kelly; Graeme Henderson
Journal:  Mol Pharmacol       Date:  2006-05-08       Impact factor: 4.436

6.  Increased response to morphine in mice lacking protein kinase C epsilon.

Authors:  P M Newton; J A Kim; A J McGeehan; J P Paredes; K Chu; M J Wallace; A J Roberts; C W Hodge; R O Messing
Journal:  Genes Brain Behav       Date:  2006-08-07       Impact factor: 3.449

7.  Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.

Authors:  A N M Schoffelmeer; F Hogenboom; G Wardeh; T J De Vries
Journal:  Neuropharmacology       Date:  2006-06-30       Impact factor: 5.250

8.  Determination of the role of conventional, novel and atypical PKC isoforms in the expression of morphine tolerance in mice.

Authors:  Forrest L Smith; Bichoy H Gabra; Paul A Smith; Marcia C Redwood; William L Dewey
Journal:  Pain       Date:  2006-09-11       Impact factor: 6.961

9.  Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation.

Authors:  Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  Mol Pharmacol       Date:  2007-10-18       Impact factor: 4.436

10.  Involvement of the protein kinase Cgamma isoform in development of tolerance to nitrous oxide-induced antinociception in mice.

Authors:  Y Matsushita; M Ishikawa; K Abe; I Utsunomiya; T Chikuma; H Hojo; K Hoshi; R M Quock; K Taguchi
Journal:  Neuroscience       Date:  2007-08-02       Impact factor: 3.590

View more
  37 in total

1.  Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells.

Authors:  Christian Doll; Florian Pöll; Kenneth Peuker; Anastasia Loktev; Laura Glück; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  G protein-coupled receptors: walking hand-in-hand, talking hand-in-hand?

Authors:  Henry F Vischer; Anne O Watts; Saskia Nijmeijer; Rob Leurs
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 3.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

Review 4.  cAMP guided his way: a life for G protein-mediated signal transduction and molecular pharmacology-tribute to Karl H. Jakobs.

Authors:  Klaus Aktories; Peter Gierschik; Dagmar Meyer Zu Heringdorf; Martina Schmidt; Günter Schultz; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-17       Impact factor: 3.000

5.  Chronic Treatment with Morphine Disrupts Acute Kinase-Dependent Desensitization of GPCRs.

Authors:  Emily R Leff; Seksiri Arttamangkul; John T Williams
Journal:  Mol Pharmacol       Date:  2020-05-03       Impact factor: 4.436

6.  FK506-binding protein 12 modulates μ-opioid receptor phosphorylation and protein kinase C(ε)-dependent signaling by its direct interaction with the receptor.

Authors:  Yu Qiu; Wei Zhao; Yan Wang; Jian-Rong Xu; Eddie Huie; Shan Jiang; Ying-Hui Yan; Horace H Loh; Hong-Zhuan Chen; Ping-Yee Law
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

Review 7.  Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons.

Authors:  Vu C Dang; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

8.  Role of FK506 binding protein 12 in morphine-induced μ-opioid receptor internalization and desensitization.

Authors:  Ying-Hui Yan; Yan Wang; Lan-Xue Zhao; Shan Jiang; Horace H Loh; Ping-Yee Law; Hong-Zhuan Chen; Yu Qiu
Journal:  Neurosci Lett       Date:  2014-03-06       Impact factor: 3.046

Review 9.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

10.  Presynaptic mGluRs Control the Duration of Endocannabinoid-Mediated DSI.

Authors:  Phillip L W Colmers; Jaideep S Bains
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.